COVID-19 has compelled medtech manufacturers, and regulators and governments too, to take a good look at what they do, and assess how they can do it better. Many have also been openly asking why haven’t they done it better. There is nothing like a crisis to focus the mind.
More open regulatory pathways have given medtechs the scope to innovate more rapidly. There are examples aplenty of turbocharged product...







